Junctional Adhesion Molecules: Potential Proteins in Atherosclerosis

Wang, Junqi; Chen, Xiaoping

doi:10.3389/fcvm.2022.888818

Cited by 4 publications

(2 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Junctional adhesion molecule-A (JAM-A), also known as the F11 receptor (F11R), is one of the TJ components (Kornecki et al, 1990;Martìn-Padura et al, 1998) and is also expressed on circulating platelets and leukocytes (Wang and Chen, 2022). Shortly, JAM-A is a transmembrane glycoprotein that contains an extracellular region at the Nterminus with two immunoglobulin (Ig)-like domains, a transmembrane segment, and a short cytosolic tail at the Cterminus (Martìn-Padura et al, 1998;Prota et al, 2003;Steinbacher et al, 2018).…”

Section: Introductionmentioning

confidence: 99%

“…Moreover, it regulates many cellular processes, including angiogenesis (Naik et al, 2008), cell migration (Azari et al, 2010;Wang and Liu, 2022) and adhesion (Mandell et al, 2005), leukocyte transendothelial migration (Corada et al, 2005;Khandoga et al, 2005), intercellular permeability (Laukoetter et al, 2007), epithelial-tomesenchymal transition (EMT) (Communal et al, 2020) and platelet activation (Babinska et al, 2002). In the literature, JAM-A is described as a protein involved in the pathogenesis of neurological disorders (Padden et al, 2007), cardiovascular diseases (Babinska et al, 2019;Koenen and Weber, 2022;Rath et al, 2022;Wang and Chen, 2022), rheumatoid arthritis (Fang et al, 2016), inflammatory bowel disease (Vetrano and Danese, 2009), and many types of neoplastic diseases including breast (McSherry et al, 2009;Murakami et al, 2011;Vellanki et al, 2019;Bednarek et al, 2020;Vences-Catalan et al, 2021;Smith et al, 2022), lung (Magara et al, 2017;Zhao et al, 2017), nasopharyngeal (Jiang et al, 2019;Dai et al, 2021), head and neck (Kurose et al, 2016;Kakiuchi et al, 2021), testicular (Tarulli et al, 2013), thyroid (Orlandella et al, 2019), colorectal (Caykara et al, 2019;Lampis et al, 2021), gastric (Huang et al, 2014), endometrial (Koshiba et al, 2009), cervical (Akimo...…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Junctional adhesion molecule-A (JAM-A) in gynecological cancers: Current state of knowledge

Czubak-Prowizor¹,

Świątkowska²

2023

Biocell

View full text Add to dashboard Cite

Junctional adhesion molecule-A (JAM-A), also known as the F11 receptor (F11R), is one of the tight junction components. JAM-A is a transmembrane glycoprotein that regulates many cellular processes, i.e., angiogenesis, leukocyte transendothelial migration, intercellular permeability, epithelial-to-mesenchymal transition, and platelet activation. Of note, it is involved in the pathogenesis of various cancer types, including gynecological cancers. Only a few studies are available about this cancer type. Observed aberrant JAM-A expression in gynecological cancers correlates with poor patient prognosis. To the best of our knowledge, conflicting JAM-A roles in various cancer types suggest that its involvement is complex and tumor-type specific. The underlying molecular mechanisms and pathways responsible for JAM-A functions were not fully elucidated and need to be identified. Finding appropriate novel molecular cancer biomarkers may reduce observed very high mortality rates and could contribute to personalized treatment development. The main aim of the present viewpoint article is to report the current knowledge about JAM-A participation in gynecological malignancies.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Junctional adhesion molecule-A (JAM-A) in gynecological cancers: Current state of knowledge

Czubak-Prowizor¹,

Świątkowska²

2023

Biocell

View full text Add to dashboard Cite

show abstract

The Specific Molecular Changes Induced by Diabetic Conditions in Valvular Endothelial Cells and upon Their Interactions with Monocytes Contribute to Endothelial Dysfunction

Tucureanu,

Ciortan,

Macarie

et al. 2024

IJMS

View full text Add to dashboard Cite

Aortic valve disease (AVD) represents a global public health challenge. Research indicates a higher prevalence of diabetes in AVD patients, accelerating disease advancement. Although the specific mechanisms linking diabetes to valve dysfunction remain unclear, alterations of valvular endothelial cells (VECs) homeostasis due to high glucose (HG) or their crosstalk with monocytes play pivotal roles. The aim of this study was to determine the molecular signatures of VECs in HG and upon their interaction with monocytes in normal (NG) or high glucose conditions and to propose novel mechanisms underlying valvular dysfunction in diabetes. VECs and THP-1 monocytes cultured in NG/HG conditions were used. The RNAseq analysis revealed transcriptomic changes in VECs, in processes related to cytoskeleton regulation, focal adhesions, cellular junctions, and cell adhesion. Key molecules were validated by qPCR, Western blot, and immunofluorescence assays. The alterations in cytoskeleton and intercellular junctions impacted VEC function, leading to changes in VECs adherence to extracellular matrix, endothelial permeability, monocyte adhesion, and transmigration. The findings uncover new molecular mechanisms of VEC dysfunction in HG conditions and upon their interaction with monocytes in NG/HG conditions and may help to understand mechanisms of valvular dysfunction in diabetes and to develop novel therapeutic strategies in AVD.

show abstract

Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment

Romano

Rosa

Fioretto

et al. 2022

Life

View full text Add to dashboard Cite

Systemic sclerosis (SSc, scleroderma) is a severe disease characterized by peripheral microcirculation abnormalities manifesting with Raynaud’s phenomenon, nailfold videocapillaroscopic (NVC) changes, and even ischemic digital ulcers (DUs) that are often refractory to treatments. In the wake of previously described associations between the circulating levels of soluble junctional adhesion molecules (sJAMs) and SSc clinical features, here, we measured sJAM-A and sJAM-C levels by enzyme-linked immunosorbent assay in serum samples from a large case series of 110 SSc patients and 85 healthy controls, focusing on their possible association with peripheral vascular clinical features and their potential as biomarkers that are either diagnostic or mirror SSc-related microvasculopathy severity. Our data demonstrated that serum sJAM-A and sJAM-C are significantly increased in patients with SSc vs. healthy controls, especially in those featuring early/active NVC patterns and the presence of ischemic DUs. Moreover, circulating sJAM-C levels showed good diagnostic accuracy in discriminating between patients and controls, as assessed by receiver operator characteristics curve analysis. Finally, logistic regression revealed that, when comparing sJAM-A to sJAM-C, the latter might be better suited as a biomarker for SSc-related DUs. Our promising findings provide the necessary groundwork for longitudinal follow-up analyses of SSc patients aiming to assess whether circulating sJAM-C levels might be predictive for the development of new DUs, as well as DU recurrence and/or refractoriness to targeted therapies.

show abstract

Junctional Adhesion Molecules: Potential Proteins in Atherosclerosis

Cited by 4 publications

References 171 publications

Junctional adhesion molecule-A (JAM-A) in gynecological cancers: Current state of knowledge

Junctional adhesion molecule-A (JAM-A) in gynecological cancers: Current state of knowledge

The Specific Molecular Changes Induced by Diabetic Conditions in Valvular Endothelial Cells and upon Their Interactions with Monocytes Contribute to Endothelial Dysfunction

Increased Circulating Soluble Junctional Adhesion Molecules in Systemic Sclerosis: Association with Peripheral Microvascular Impairment

Contact Info

Product

Resources

About